-- Syntara（ASX：SNT）週二向澳洲證券交易所提交的文件顯示，在C類會議上，美國食品藥物管理局（FDA）給予了正面回饋，支持其針對骨髓纖維化治療藥物amsulostat的2b期臨床試驗方案設計。 文件指出，2b期臨床試驗的主要終點是治療9個月後總症狀評分降低50%，預計招募約100名患者。 該公司表示，美國FDA的積極回饋使得amsulostat得以進入後期臨床開發階段，並為與潛在商業夥伴的進一步合作鋪平了道路。 骨髓纖維化是一種骨髓癌，其特徵是疤痕組織的積聚導致紅血球、白血球和血小板減少。
Related Articles
Asia
Rate Increases Have Limited Impact on Japanese Borrowers' Credit Quality, S&P Says
Increasing interest rates will not have a significant effect on Japanese borrowers' creditworthiness, although repayment burdens could intensify if the rise in rates continues, S&P Global Ratings said in a Tuesday release.The rating agency expects limited impact on repayment capacity from higher interest rates as residential mortgage-backed securities (RMBS) are usually backed by fixed-rate housing loans, S&P said.However, rate increases could heighten total borrowing, especially under increased real estate prices, S&P said.The spike in housing prices is likely due to increased employment costs and a sustained rise in imported material prices, the rating agency said.Still, S&P expects that even under the most severe stress scenario, tranches to be downgraded would only have a 17% share of all rated RMBS transactions and still lead to ratings of A+ or higher.
$^N225
Equities
Market Chatter: Eni, Repsol Seek to Increase Venezuela Gas Production
Eni (E) and Repsol seek to increase production at their jointly Cardon IV gas field in Venezuela to 645 million cubic feet per day, Reuters reported Monday, citing comments by the project manager at a conference.Gonzalo Antonio Carrillos said the field currently produces about 580 million cubic feet per day without saying when it would reach the higher threshold, Reuters reported.Speaking at the conference, Venezuela vice minister for gas Cindy Rondon said the country needs to speed up repairs to its gas infrastructure, the report said.Eni and Repsol did not immediately reply to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
$E
Asia
Mitsubishi Electric's Fiscal-Year Profit Jumps 26%
Mitsubishi Electric's (TYO:6503) profit attributable to owners of the parent jumped 26% to 407.7 billion yen for the fiscal year ended March 31 from 324 billion yen a year earlier.The electronics company's earnings per share increased to 198.31 yen from 155.70 yen a year ago, according to a Tokyo bourse filing on Tuesday.Revenue climbed 7% to 5.895 trillion yen from 5.522 trillion yen in the prior year.It declared a final dividend of 30 yen per share for the fiscal 2026, payable from June 2.For the fiscal year ending March 31, 2027, the company expects attributable profit of 475 billion yen and net sales of 6.2 trillion yen.Mitsubishi Electric plans to pay interim and year-end dividends of 25 yen and 30 yen per share, respectively, for the current fiscal year (total 55 yen), which is higher than the amount paid in the year-ago period.
$TYO:6503